CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CLAIMS focuses on developing a diagnostic platform for multiple sclerosis that utilizes clinical and subclinical biomarkers to predict disease progression and treatment response. This aims to enhance personalized treatment approaches and improve patient outcomes.
Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system.
Since there is no cure available yet for MS, the primary therapeutic goal for MS patients is to slow down disability progression and to reduce relapses at early stages of the disease.
Despite 19 available disease modifying treatments (DMTs), the large heterogeneity of the disease, further complicated by the high prevalance of comorbidities and multipharmacy, and the limited understanding of the worki…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Madrid
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Leuven
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Bochum
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Dresden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
